<p>加利福尼亚州圣地亚哥 / ACCESS Newswire /2025 年 12 月 4 日/ Dermata Therapeutics, Inc.（&#34;Dermata&#34;或&#34;公司&#34;），一家以科学为驱动的皮肤科解决方案领导者，今天宣布将很快揭晓其非处方（&#34;OTC&#34;）护肤业务的新品牌名称，代表其向更直接、以科学为首的皮肤科创新时代的演变。虽然该名称在正式揭晓之前仍然保密，但公司提供了一个关于推动这一新身份的使命和本质的初步了解——这一身份专为期望从产品、科学和背后的公司中获得更多的护肤消费者社区而创建。</p>
<p>致力于开创一个强大而非惩罚性的护肤新领域。</p>
<p>Dermata 的使命是通过将祖传智慧与科学创新相结合，重新定义皮肤科的可能性，从而创造出一种全新的类别方法。Dermata 希望赋予人们体验一种全新效能的能力，而这种效能绝不会以健康和福祉为代价。</p>
<p>他们的使命为新品牌名称及其伴随的视觉和语言表达奠定了基础。Dermata 的疗法、技术和产品体验将通过一种诚实、自信且毫不妥协地根植于可量化表现的视角来框架。</p>
<p><strong>为好奇者而建。</strong></p>
<p>当今的精明护肤消费者不再满足于被动的护肤程序或模糊的承诺。他们将临床严谨与体验直觉相结合；他们对机制的理解与对质地的欣赏同样深刻；他们寻求既经典又前沿的解决方案，以释放新的可能性。Dermata 计划针对这些对所用产品有深入研究好奇心的消费者。他们是成熟的采用者，想要了解产品的工作原理、成分以及效果。</p>
<p>Dermata 的新品牌身份是以这些好奇的个体为中心塑造的。它呼应了一代人，他们提出更好的问题，要求更好的答案，并期待更好的科学，这与 Dermata 的建立方式相似。</p>
<p><strong>提供指数级成果的产品。</strong></p>
<p>Dermata 旨在开发一系列对有效护肤程序至关重要的产品。他们相信，在一个充满过于复杂且效果不佳的治疗方案的世界中，结合他们的_Spongilla_技术将挑战并重塑消费者的护肤方式。公司计划通过创造高效、有效的产品，使护肤程序的每个部分都能更好地发挥作用。</p>
<p>Dermata 希望消费者在使用其产品时能感受到护肤程序的提升。</p>
<p><strong>一个体现这一雄心的名称。</strong></p>
<p>虽然 Dermata 在正式揭晓之前仍然保密品牌名称，但公司暗示该名称捕捉了：</p>
<ul>
<li>经得起时间考验的疗法</li>
<li>持续的创新</li>
<li>相信真正的肌肤转变始于有目的的科学</li>
</ul>
<p>这一揭晓预计将标志着一个新篇章的开始——一个由更强的消费者对齐、更清晰的产品差异化和围绕创新的更明确叙述所定义的篇章。</p>
<p><strong>展望未来。</strong></p>
<p>Dermata 将在接下来的几周内揭晓新品牌名称和身份。包括视觉资产、产品定位和发布阶段沟通在内的更多信息将在未来几个月内分享。公司计划在 2026 年中期推出其首个 OTC 每周一次的痤疮套件。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中不严格属于历史性质的声明为前瞻性声明。这些声明基于公司的当前信念和预期，并且可能会不时出现新的风险。前瞻性声明受到已知和未知的风险、不确定性、假设和其他因素的影响，包括但不限于与以下内容相关的声明：Dermata 转变为优先考虑 OTC 皮肤科产品；任何未来公告的时间；Dermata 战略转变的预期好处，包括加速其商业化路径、减少监管负担以及扩展到更广泛的消费市场；任何计划或未来 OTC 产品发布的预期时间和成功；消费者对 Dermata 任何产品候选的接受程度；以及公司在证券交易委员会的备案中描述的其他因素。这些前瞻性声明通常通过使用&#34;可能&#34;、&#34;可以&#34;、&#34;应该&#34;、&#34;会&#34;、&#34;相信&#34;、&#34;预期&#34;、&#34;预测&#34;、&#34;估计&#34;、&#34;期待&#34;、&#34;打算&#34;、&#34;计划&#34;、&#34;继续&#34;、&#34;展望&#34;、&#34;将&#34;、&#34;潜在&#34;及类似的未来或前瞻性性质的声明来识别。这些声明仅是基于当前信息和预期的预测，并涉及许多风险和不确定性。实际事件或结果可能因各种因素而与任何此类声明中预测的结果有重大差异，包括药物开发、批准和商业化固有的风险和不确定性，以及临床试验的过去结果可能不代表未来试验结果的事实。有关这些和其他因素的讨论，请参阅 Dermata 在证券交易委员会的备案。您被警告不要对这些前瞻性声明过度依赖，这些声明仅在本日期时有效。此警告是根据 1995 年《私人证券诉讼改革法》的安全港条款作出的。所有前瞻性声明均完全受到此警告声明的限制，Dermata 没有义务修订或更新本新闻稿，以反映本日期后的事件或情况，除非法律要求。</p>
<p><strong>Dermata 投资者：</strong></p>
<p>Cliff Mastricola</p>
<p>投资者关系</p>
<p>cmastricola@dermatarx.com</p>
<p><strong>来源：</strong> Dermata Therapeutics</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>

DRMA

<p>Dermata Therapeutics, Inc. 宣布计划为其 OTC 护肤系列推出全新的品牌形象，强调以科学驱动的皮肤病学创新。该品牌旨在通过结合传统智慧与科学创新来重新定义护肤，目标是满足那些对科学和效果有更高要求的消费者。新的品牌形象将很快揭晓，首个 OTC 痘痘护理套件预计在 2026 年中旬推出。前瞻性声明提醒有关产品开发和商业化中的风险和不确定性</p>

<p>SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc.  (&#34;Dermata&#34; or the &#34;Company&#34;), a science-driven leader in dermatologic solutions, today announced that it will soon reveal its new brand name for its over-the-counter (&#34;OTC&#34;) skincare business representing its evolution toward a more direct, science-first era of dermatologic innovation. While the name remains confidential until the formal unveiling, the Company is offering a first look at the mission and essence driving this new identity-one created specifically for the community of <em>skincare consumers</em> who expect more from their products, their science, and the companies behind them.</p>
<div class="lb-trans"><p>加利福尼亚州圣地亚哥 / ACCESS Newswire /2025 年 12 月 4 日/ Dermata Therapeutics, Inc.（&#34;Dermata&#34;或&#34;公司&#34;），一家以科学为驱动的皮肤科解决方案领导者，今天宣布将很快揭晓其非处方（&#34;OTC&#34;）护肤业务的新品牌名称，代表其向更直接、以科学为首的皮肤科创新时代的演变。虽然该名称在正式揭晓之前仍然保密，但公司提供了一个关于推动这一新身份的使命和本质的初步了解——这一身份专为期望从产品、科学和背后的公司中获得更多的护肤消费者社区而创建。</p>
</div><p>On a mission to forge a new realm of skincare that is powerful, not punishing.</p>
<div class="lb-trans"><p>致力于开创一个强大而非惩罚性的护肤新领域。</p>
</div><p>Dermata's mission is to redefine what's possible in dermatology by melding ancestral wisdom with scientific innovation to create an entirely new approach to the category. Dermata wants to empower people to experience a new form of potency that never comes at the expense of health and wellbeing.</p>
<div class="lb-trans"><p>Dermata 的使命是通过将祖传智慧与科学创新相结合，重新定义皮肤科的可能性，从而创造出一种全新的类别方法。Dermata 希望赋予人们体验一种全新效能的能力，而这种效能绝不会以健康和福祉为代价。</p>
</div><p>Their mission serves as the foundation for the new brand name and its accompanying visual and verbal expression. Dermata's therapies, technologies, and product experiences will be framed through a lens that is honest, confident, and uncompromisingly rooted in quantifiable performance.</p>
<div class="lb-trans"><p>他们的使命为新品牌名称及其伴随的视觉和语言表达奠定了基础。Dermata 的疗法、技术和产品体验将通过一种诚实、自信且毫不妥协地根植于可量化表现的视角来框架。</p>
</div><p><strong>Built for the curious.</strong></p>
<div class="lb-trans"><p><strong>为好奇者而建。</strong></p>
</div><p>Today's sophisticated skincare consumer is no longer content with passive routines or vague promises. They blend clinical rigor with experiential intuition; they understand mechanisms as deeply as they appreciate textures; they seek solutions that are timeless and cutting edge to unleash a new realm of possibilities. Dermata plans to target these consumers who have a deep curiosity to research the products they are putting on their skin. They are mature adopters who want to know how the product works, what are the ingredients, and what are the results.</p>
<div class="lb-trans"><p>当今的精明护肤消费者不再满足于被动的护肤程序或模糊的承诺。他们将临床严谨与体验直觉相结合；他们对机制的理解与对质地的欣赏同样深刻；他们寻求既经典又前沿的解决方案，以释放新的可能性。Dermata 计划针对这些对所用产品有深入研究好奇心的消费者。他们是成熟的采用者，想要了解产品的工作原理、成分以及效果。</p>
</div><p>Dermata's new brand identity was shaped with these curious individuals in mind. It speaks to a generation that asks better questions, demands better answers, and expects better science, similar to how Dermata was built.</p>
<div class="lb-trans"><p>Dermata 的新品牌身份是以这些好奇的个体为中心塑造的。它呼应了一代人，他们提出更好的问题，要求更好的答案，并期待更好的科学，这与 Dermata 的建立方式相似。</p>
</div><p><strong>With products that deliver exponential results.</strong></p>
<div class="lb-trans"><p><strong>提供指数级成果的产品。</strong></p>
</div><p>Dermata aims to develop a line of products that are essential for an effective skincare routine. They believe that in a world filled with treatments that overcomplicate and underdeliver, incorporating their <em>Spongilla</em> technology will challenge and reshape how consumers care for their skin. The Company plans to accomplish this by creating products that are efficient, effective, and make every other part of a skincare routine work better.</p>
<div class="lb-trans"><p>Dermata 旨在开发一系列对有效护肤程序至关重要的产品。他们相信，在一个充满过于复杂且效果不佳的治疗方案的世界中，结合他们的_Spongilla_技术将挑战并重塑消费者的护肤方式。公司计划通过创造高效、有效的产品，使护肤程序的每个部分都能更好地发挥作用。</p>
</div><p>Dermata wants consumers to feel the difference when using their products that amplify their skincare routine.</p>
<div class="lb-trans"><p>Dermata 希望消费者在使用其产品时能感受到护肤程序的提升。</p>
</div><p><strong>A name that embodies this ambition.</strong></p>
<div class="lb-trans"><p><strong>一个体现这一雄心的名称。</strong></p>
</div><p>While Dermata is keeping the brand name confidential ahead of its official reveal, the Company hints that the name captures:</p>
<div class="lb-trans"><p>虽然 Dermata 在正式揭晓之前仍然保密品牌名称，但公司暗示该名称捕捉了：</p>
</div><ul>
<li>Time-tested remedies</li>
<li>Perpetual innovation</li>
<li>Belief that true skin transformation begins with purposeful science</li>
</ul>
<div class="lb-trans"><ul>
<li>经得起时间考验的疗法</li>
<li>持续的创新</li>
<li>相信真正的肌肤转变始于有目的的科学</li>
</ul>
</div><p>The reveal is expected to signal the beginning of a new chapter-one defined by stronger consumer alignment, clearer product differentiation, and a sharpened narrative around innovation.</p>
<div class="lb-trans"><p>这一揭晓预计将标志着一个新篇章的开始——一个由更强的消费者对齐、更清晰的产品差异化和围绕创新的更明确叙述所定义的篇章。</p>
</div><p><strong>Looking ahead.</strong></p>
<div class="lb-trans"><p><strong>展望未来。</strong></p>
</div><p>Dermata will unveil the new brand name and identity in the coming weeks. Additional information, including visual assets, product positioning, and launch-phase communications, will be shared over the coming months. The Company plans to launch its first OTC once-weekly acne kit in the middle of 2026.</p>
<div class="lb-trans"><p>Dermata 将在接下来的几周内揭晓新品牌名称和身份。包括视觉资产、产品定位和发布阶段沟通在内的更多信息将在未来几个月内分享。公司计划在 2026 年中期推出其首个 OTC 每周一次的痤疮套件。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to prioritize OTC dermatology products; the timing of any future announcement; the anticipated benefits of Dermata's strategic shift, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the expected timing and success of any planned or future OTC product launches; consumer acceptance of any of Dermata's product candidates; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;would,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;forecast,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;plan,&#34; &#34;continue,&#34; &#34;outlook,&#34; &#34;will,&#34; &#34;potential&#34; and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿中不严格属于历史性质的声明为前瞻性声明。这些声明基于公司的当前信念和预期，并且可能会不时出现新的风险。前瞻性声明受到已知和未知的风险、不确定性、假设和其他因素的影响，包括但不限于与以下内容相关的声明：Dermata 转变为优先考虑 OTC 皮肤科产品；任何未来公告的时间；Dermata 战略转变的预期好处，包括加速其商业化路径、减少监管负担以及扩展到更广泛的消费市场；任何计划或未来 OTC 产品发布的预期时间和成功；消费者对 Dermata 任何产品候选的接受程度；以及公司在证券交易委员会的备案中描述的其他因素。这些前瞻性声明通常通过使用&#34;可能&#34;、&#34;可以&#34;、&#34;应该&#34;、&#34;会&#34;、&#34;相信&#34;、&#34;预期&#34;、&#34;预测&#34;、&#34;估计&#34;、&#34;期待&#34;、&#34;打算&#34;、&#34;计划&#34;、&#34;继续&#34;、&#34;展望&#34;、&#34;将&#34;、&#34;潜在&#34;及类似的未来或前瞻性性质的声明来识别。这些声明仅是基于当前信息和预期的预测，并涉及许多风险和不确定性。实际事件或结果可能因各种因素而与任何此类声明中预测的结果有重大差异，包括药物开发、批准和商业化固有的风险和不确定性，以及临床试验的过去结果可能不代表未来试验结果的事实。有关这些和其他因素的讨论，请参阅 Dermata 在证券交易委员会的备案。您被警告不要对这些前瞻性声明过度依赖，这些声明仅在本日期时有效。此警告是根据 1995 年《私人证券诉讼改革法》的安全港条款作出的。所有前瞻性声明均完全受到此警告声明的限制，Dermata 没有义务修订或更新本新闻稿，以反映本日期后的事件或情况，除非法律要求。</p>
</div><p><strong>Dermata Investors:</strong></p>
<div class="lb-trans"><p><strong>Dermata 投资者：</strong></p>
</div><p>Cliff Mastricola</p>
<div class="lb-trans"><p>Cliff Mastricola</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>cmastricola@dermatarx.com</p>
<div class="lb-trans"><p>cmastricola@dermatarx.com</p>
</div><p><strong>SOURCE:</strong> Dermata Therapeutics</p>
<div class="lb-trans"><p><strong>来源：</strong> Dermata Therapeutics</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div>

护肤品的新领域即将到来：Dermata 预告新的非处方药品牌形象